title: Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis.
abstract: The goal of the present study was to analyze the potential application of nonviral vectors based on solid lipid nanoparticles (SLN) for the treatment of ocular diseases by gene therapy, specifically X-linked juvenile retinoschisis (XLRS). Vectors were prepared with SLN, dextran, protamine, and a plasmid (pCMS-EGFP or pCEP4-RS1). Formulations were characterized and the in vitro transfection capacity as well as the cellular uptake and the intracellular trafficking were studied in ARPE-19 cells. Formulations were also tested in vivo in Wistar rat eyes, and the efficacy was studied by monitoring the expression of enhanced green fluorescent protein (EGFP) after intravitreal, subretinal, and topical administration. The presence of dextran and protamine in the SLN improved greatly the expression of retinoschisin and EGFP in ARPE-19 cells. The nuclear localization signals of protamine, its ability to protect the DNA, and a shift in the entry mechanism from caveola-mediated to clathrin-mediated endocytosis promoted by the dextran, justify the increase in transfection. After ocular administration of the dextran-protamine-DNA-SLN complex to rat eyes, we detected the expression of EGFP in various types of cells depending on the administration route. Our vectors were also able to transfect corneal cells after topical application. We have demonstrated the potential usefulness of our nonviral vectors loaded with XLRS1 plasmid and provided evidence for their potential application for the management or treatment of degenerative retinal disorders as well as ocular surface diseases.
authors.affiliation: Pharmacokinetics, Nanotechnology and Gene Therapy Group Laboratory of Pharmacy and Pharmaceutical Technology, University of the Basque Country UPV/EHU, 01006 Vitoria-Gasteiz, Spain.
authors.forename: Diego
authors.initials: D
authors.lastname: Delgado
authors.forename: Ana
authors.initials: A
authors.lastname: del Pozo-Rodríguez
authors.forename: Maria Ángeles
authors.initials: MÁ
authors.lastname: Solinís
authors.forename: Marcelino
authors.initials: M
authors.lastname: Avilés-Triqueros
authors.forename: Bernhard H F
authors.initials: BH
authors.lastname: Weber
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fernández
authors.forename: Alicia R
authors.initials: AR
authors.lastname: Gascón
mesh_terms: D000818:Animals; D004247:DNA / Q000008:administration & dosage; D003911:Dextrans / Q000737:chemistry*; D004337:Drug Carriers; D015316:Genetic Therapy / Q000379:methods*; D005989:Glycerides / Q000737:chemistry*; D049452:Green Fluorescent Proteins / Q000235:genetics; D053758:Nanoparticles; D010316:Particle Size; D011479:Protamines / Q000737:chemistry*; D051381:Rats; D041441:Retinoschisis / Q000235:genetics / Q000628:therapy*; D014162:Transfection
chemical_list: D003911:Dextrans; D004337:Drug Carriers; D005989:Glycerides; D011479:Protamines; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D004247:DNA